Psychedelic-assisted Group Program for First Responders

Inclusion Criteria:

• Male or female, 19 to 65 years of age

• Must be a first responder, any work status (Employed full-time or part-time,Off-work, Retired, Volunteer)

• Fluent in English

• Able to understand the informed consent form, study procedures and willing toparticipate in study

• Clinically diagnosed with a mental health condition such as:

1. Depression

2. Chronic anxiety

3. Obsessive-compulsive disorder

4. PTSD

5. Unresolved grief

6. Adjustment Disorder

7. Acute Stress Disorder

• Stable dose of medications for the last three months, with no changes anticipatedfor the duration of the study

• Medical clearance by the Investigator (MD) prior to study enrollment

• Willing and able to attend two in-person sessions throughout the 12-week program, inaddition to remote sessions

• Concurrent therapy is allowed if the type and frequency of the therapy has beenstable for at least two months prior to screening and is expected to remain stableduring participation in the study.

• Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at theresearch unit on Week 10. If the participant does not routinely consume caffeinatedbeverages, he/she must agree not to do so on Week 10.

• Agree that for one week before the drug sessions, he/she will refrain from takingany nonprescription medication, nutritional supplement, or herbal supplement (specifically SAM-e, 5-HTP, L-tryptophan, St John's Wort) except when approved bythe study Investigator. Exceptions will be evaluated by the Investigator and mayinclude acetaminophen, non-steroidal anti-inflammatory drugs, and common doses ofvitamins and minerals.

• Agree to refrain from consuming alcohol within two days prior to the Week 10 visit.

• Agree not to take any "as needed" medications on the morning of the Week 10 visit.

• Agree to use of highly effective methods of contraception during the study (females)

• Normal body mass index (BMI 18.5-24.9)

Exclusion Criteria:

• Current or past history of schizophrenia, psychotic disorder (unless substanceinduced or due to a medical condition), bipolar disorder, delusional disorder,dissociative disorder, paranoid personality disorder, schizoaffective disorder,borderline personality disorder, anorexia nervosa, bulimia nervosa or substanceabuse, as assessed by medical history

• Presence of active psychotic symptoms

• Currently diagnosed psychotic disorder in first-degree relatives, not includingpsychotic disorders secondary to an apparent medical reason, e.g. brain injury,dementia, or lesions of the brain, as assessed by medical history.

• Diagnosis of dementia or delirium

• Risk of suicide as determined by the Investigator

• Significantly intrusive PTSD as determined by the Investigator

• Extreme emotional lability can be disruptive to the group milieu and is a relativeexclusion criterion

• Uncontrolled cardiopulmonary disease, cardiovascular disease, or hypertension

• Any other clinically significant cardiovascular, pulmonary, gastrointestinal,hepatic, renal, vascular or any other major concurrent illness that, in the opinionof the Investigator, may interfere with the interpretation of the study results orconstitute a health risk for the participant if he/she takes part in the study

• Psychoactive substance use (MDMA, psilocybin, LSD) within the previous two months.

• If female and of child-bearing potential: pregnant, suspected or planning to becomepregnant during the study

• Participation in another clinical trial (currently or within the last 30 days)

• Current use of rifamycins (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, taxol,dexamethasone); cytochrome P450 Inhibitors - including all HIV protease inhibitors,verapamil, diltiazem, itraconazole, ketoconazole, erythromycin, clarithromycin,azithromycin, and troleandomycin; ergot alkaloids, pimozide, midazolam, triazolam,lovastatin, simvastatin, fentanyl, warfarin, metoprolol, propranolol, buspirone,tramadol, selegiline, sumatriptan.

• Current use of inhibitors of UGT1A9 and 1A10, monoamine oxidase inhibitors (MAOIs),Tricyclic antidepressants, aldehyde dehydrogenase inhibitors (ALDHs) and alcoholdehydrogenase inhibitors (ADHs).